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Abhinav Goyal, MDc, and Janani Rangaswami, MDa,d
aDepartment of Medicine, Einstein Medical Center, Philadelphia, Pennsylvania; bDivision of Cardiology, Baylor University Medical Center,
Dallas, Texas; cDepartment of Gastroenterology and Hepatology, Einstein Medical Center, Philadelphia, Pennsylvania; dDepartment of
Nephrology, Sidney Kimmel College of Thomas Jefferson University, Philadelphia, Pennsylvania
ABSTRACT
This systematic review analyzed whether the presence or absence of gastrointestinal symptoms in patients with SARS-COV-2
infection is associated with adverse outcomes. Searching the Cochrane Center Register of Controlled Trials, we included any
studies looking at patients with COVID-19 with gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal pain) compared
to those with COVID-19 but without gastrointestinal manifestations as a control group. The final search yielded 186 articles, all
of which were individually screened. Seven studies were identified but three were excluded: one due to lack of a control group
without gastrointestinal symptoms, one reported as viral RNA in the stool, and one with only non-critically ill patients. Results of
the meta-analysis showed a pooled odds ratio for mortality among those with COVID-19 and gastrointestinal symptoms of 0.91
(confidence interval 0.49–1.68) with heterogeneity of 0% and a pooled odds ratio for acute respiratory distress syndrome of
2.94 (confidence interval 1.17–7.40) with heterogeneity of 0%. In conclusion, gastrointestinal symptoms with COVID-19 are asso-
ciated with a higher risk of acute respiratory distress syndrome, but do not increase the risk for mortality.
KEYWORDS Abdominal pain; acute respiratory distress syndrome; diarrhea; pandemic; SARS-COV-2
D
espite the large scale of the severe acute respira-
tory syndrome coronavirus 2 (SARS-COV-2)
pandemic, little is known about the disease’s clin-
ical manifestations, natural history, routes of
transmission, and progression. Large retrospective epidemio-
logical studies in the Wuhan population have found most
infections to present with fever, fatigue, dry cough, and other
pulmonary symptoms.1 Gastrointestinal (GI) manifestations
have been reported without respiratory disease.2 Viral tro-
pism for the angiotensin-converting enzyme receptor 2
(ACE2 receptor) found in the GI tract has been proposed as
a potential mechanism for the virus affecting the GI system.3
Furthermore, fecal-oral transmission has also been postu-
lated, given the presence of viral RNA in stool samples.4 The
clinical significance of GI signs and symptoms remains
unknown, with limited and conflicting retrospective analyses
comparing patients with and without enteric findings. This
systematic review and meta-analysis explored the current
associations of GI symptoms to outcomes of mortality and
acute respiratory distress syndrome (ARDS) among patients
with COVID-19.
METHODS
We searched the Cochrane Central Register of
Controlled Trials in the Cochrane Library, PubMed, with no
restrictions based on language, date, publication status, or
any other trial characteristics. Specific search terms used were
“COVID” OR “COVID19” OR “Coronavirus” OR
“SARSCOV2” AND “gastrointestinal” OR “digestive” in the
title and/or abstract. References within the primary selected
studies that had full-text manuscripts were also screened.
Eligibility criteria included studies looking at patients with
COVID-19 with GI symptoms (nausea, vomiting, diarrhea,
abdominal pain) compared to those with COVID-19 but
without GI manifestations as a control group. We included
both prospective and observational retrospective studies; no
randomized trials were identified. Case reports or case series
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that had no comparison or control groups were excluded.
We only included studies that reported on mortality and/or
ARDS as an outcome with availability of raw data or clinical
information on mortality and ARDS data.
Two authors (FG and JP) independently screened each
title and abstract. If there was uncertainty with evaluation of
those elements, the full text was also reviewed. All screened
studies were assessed for inclusion in accordance with the
eligibility criteria. Disagreements were resolved by consensus
between the two screening authors, and a third author (KL)
was consulted when agreement could not be met. The stud-
ies were appraised using the Newcastle-Ottawa scale.5 The
two above authors then independently extracted data of the
included studies, including country, date of publication,
study design, and number of samples.
We calculated pooled odds ratios and confidence interval
(CI) estimates using Review Manager. Studies were weighted
according to their sample size to produce the final pooled
odds ratios. We considered a P value of 0.05 as statistically
significant. We examined mortality and ARDS as end points.
Pooled odds ratios and their 95% CI were calculated using a
random-effects model. This model was chosen since the defi-
nitions of GI symptoms differed slightly in each study.
Assessment of heterogeneity was done using I2 with low,
moderate, and high levels of heterogeneity corresponding to
I2 values of 25%, 50%, and 75% respectively.6
RESULTS
The final search yielded 186 articles, all of which were
individually screened. A total of seven studies were identified,
but three were excluded: one due to lack of a control group
without GI symptoms, one reporting viral RNA in the stool,
and one with only non-critically ill patients (Figure 1). Four
studies were included in both the qualitative and meta-anal-
ysis (Table 1);2,7–9 all of them had good quality for a non-
randomized study, accounting for possible confounders such
as demographics and comorbidities. The pooled odds ratio
for mortality among those with COVID-19 and GI symp-
toms was 0.91 (CI 0.49–1.68) with heterogeneity of 0%,
while the pooled odds ratio for ARDS was 2.94 (CI
1.17–7.40) with heterogeneity of 0% (Figure 2).
Figure 1. PRISMA diagram for the meta-analysis.
Table 1. Studies included in the meta-analysis
Study
Chinese
city
Retrospective
design
Inclusion of
suspected
vs confirmed
SARS-COV-2
GI
symptom
definition
Outcomes
Newcastle
Ottawa
scale (points)
With GI
symptoms
Without GI
symptoms
Zhou et al,
March 20208
Wuhan þ Suspected Abdominal pain,
nausea, vomiting,
or diarrhea
Death: 4/66
ARDS: 2/66
Death: 12/188
ARDS: 3/188
8
Jin et al,
March 20202
Zhejiang þ Confirmed Nausea, vomiting,
or diarrhea
ARDS: 5/74 ARDS: 12/577 8
Pan et al,
March 20207
Hubei 0 (Descriptive,
cross-sectional)
Confirmed Anorexia, vomiting,
diarrhea, or
abdominal pain
Death: 17/101 Death: 19/103 8
Lin et al,
March 20209
Zhuhai þ Confirmed Anorexia, diarrhea,
nausea, vomiting,
acid reflux,
dyspepsia, or
hepatic function
derangement
Death: 0/58
Severe disease: 14/58
Death: 0/37
Severe disease: 6/37
8
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DISCUSSION
A recent epidemiological meta-analysis by Cheung et al found
that of the 4243 patients with COVID-19, 17.6% had GI symp-
toms.10 Another Chinese population study by Tian et al reported
that anorexia was the most frequent digestive symptom in adults
(30%–50%), while the prevalence of diarrhea ranged from 2% to
50%. Some adults also presented with vomiting, while GI bleed-
ing and abdominal pain were found in more severely ill patients.11
The prevalence of GI symptoms in severely ill and non–severely
ill patients is conflicting. Fang et al reported high GI symptom
burden in both severely ill and stable patients with an incidence
of 85% and 79%, respectively.12 A similar trend was observed in
a large study of 1099 patients by Guan et al where they reported
no difference in proportion of GI symptoms in severe vs nonse-
vere cases of COVID-19.1 In contrast, a study by Wang et al
showed that the proportion of GI symptoms was significantly
higher in patients in the intensive care unit than in other hospital-
ized patients.13 However, none of these studies looked at the pres-
ence of GI signs and symptoms as possible prognostic factors for
poor outcomes such as mortality and ARDS.
Comparing patients positive for SARS-COV-2 with con-
current GI symptoms with those without GI symptoms, our
analysis found no significant difference in mortality between
the two groups, but those with GI symptoms had a signifi-
cant risk for development of ARDS. Ling et al and Xiao et al
reported persistent viral shedding in stool even after the
nasopharyngeal swabs turned negative.14,15 The presence of
GI symptoms may lead to increased exposure duration and
greater viral burden, and thus GI symptoms may serve as a
proxy for a more severely infected patient. Furthermore,
studies on ACE2 receptor expression suggest that ACE2 is
highly expressed not only in the respiratory tract, but also in
the esophagus and absorptive enterocytes from the ileum and
colon.3 Thus, the GI tract may be particularly vulnerable to
COVID-19 infection, and more extrapulmonary involve-
ment might suggest a more severe disseminated viral course
and potentially more inflammation and cytokine release,
thereby contributing to multiorgan involvement and ARDS,
as was suggested by our findings.16
There are limitations to our meta-analysis. It is based on
retrospective observational studies published on this topic at
this time; however, given the paucity of literature and conflict-
ing results from available studies on the prognostic significance
of GI involvement amidst this unprecedented rapidly evolving
pandemic, this can be a source of confusion for clinicians caring
for these patients. Our study addresses this important issue of
GI tract involvement by SARS-CoV-2 and its impact on clin-
ical outcomes and shows a significant association with ARDS.
Our findings will help clinicians triage patients better in
resource-limited settings, especially with regards to hospital
admission and level of care. Larger prospective studies are neces-
sary to elucidate the complete natural history of this disease and
to confirm our findings on a larger scale.
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